» Articles » PMID: 28494192

Prooxidant-antioxidant Balance, HsTnI and HsCRP: Mortality Prediction in Haemodialysis Patients, Two-year Follow-up

Overview
Journal Ren Fail
Publisher Informa Healthcare
Date 2017 May 12
PMID 28494192
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Oxidative stress and inflammation are highly intertwined pathophysiological processes. We analyzed the markers of these processes and high-sensitive troponin I (hsTnI) for mortality prediction in patients on haemodialysis. This study enrolled a total of 62 patients on regular haemodialysis. The patients were monitored for two years, and the observed outcomes were all-cause and cardiovascular mortality. Blood samples were taken before one dialysis session for analysis of the baseline concentrations of prooxidant-antioxidant balance (PAB), total antioxidant status (TAS), total oxidative status (TOS), hsTnI, hsCRP and resistin. The overall all-cause mortality was 37.1% and CVD mortality 16.1%. By univariate and multivariate logistic regression, our findings suggest that good predictors of all-cause mortality include hsCRP and PAB (p < .05) and of CVD mortality hsCRP (p < .05) and hsTnI (p < .001). To evaluate the relationship between the combined parameter measurements and all-cause/CVD mortality risk, patients were divided into three groups according to their PAB, hsCRP and hsTnI concentrations. The cutoffs for hsCRP and hsTnI and the median for PAB were used. Kaplan-Meier survival curves pointed out that the highest mortality risk of all-cause mortality was in the group with hsCRP levels above the cutoff and PAB levels above the median (p < .001). The highest risk of CVD mortality was found in the group with hsCRP and hsTnI levels above the cutoff levels (p = .001). Our data suggest that hsCRP and PAB are very good predictors of all-cause mortality. For CVD complications and mortality prediction in HD patients, the most sensitive parameters appear to be hsTnI and hsCRP.

Citing Articles

Risk factors for short-term all-cause mortality in patients with end stage renal disease: a scoping review.

Yip W, Ng S, Kaur P, George P, Guan J, Lee G BMC Nephrol. 2024; 25(1):71.

PMID: 38413903 PMC: 10900550. DOI: 10.1186/s12882-024-03503-3.


Redox Status and Telomere-Telomerase System Biomarkers in Patients with Acute Myocardial Infarction Using a Principal Component Analysis: Is There a Link?.

Vukasinovic A, Klisic A, Ostanek B, Kafedzic S, Zdravkovic M, Ilic I Int J Mol Sci. 2023; 24(18).

PMID: 37762611 PMC: 10531660. DOI: 10.3390/ijms241814308.


The effect of zingiber officinale on prooxidant-antioxidant balance and glycemic control in diabetic patients with ESRD undergoing hemodialysis: a double-blind randomized control trial.

Rostamkhani H, Veisi P, Niknafs B, Jafarabadi M, Ghoreishi Z BMC Complement Med Ther. 2023; 23(1):52.

PMID: 36800950 PMC: 9936709. DOI: 10.1186/s12906-023-03874-4.


NLRP3 Inflammasome: a Novel Insight into Heart Failure.

Wang Y, Li Y, Zhang W, Yuan Z, Lv S, Zhang J J Cardiovasc Transl Res. 2022; 16(1):166-176.

PMID: 35697978 DOI: 10.1007/s12265-022-10286-1.


Relationship between sex and cardiovascular mortality in chronic kidney disease: A systematic review and meta-analysis.

Shajahan S, Amin J, Phillips J, Hildreth C PLoS One. 2021; 16(7):e0254554.

PMID: 34252153 PMC: 8274915. DOI: 10.1371/journal.pone.0254554.


References
1.
Parizadeh S, Azarpazhooh M, Moohebati M, Nematy M, Ghayour-Mobarhan M, Tavallaie S . Simvastatin therapy reduces prooxidant-antioxidant balance: results of a placebo-controlled cross-over trial. Lipids. 2011; 46(4):333-40. DOI: 10.1007/s11745-010-3517-x. View

2.
Alamdari D, Paletas K, Pegiou T, Sarigianni M, Befani C, Koliakos G . A novel assay for the evaluation of the prooxidant-antioxidant balance, before and after antioxidant vitamin administration in type II diabetes patients. Clin Biochem. 2007; 40(3-4):248-54. DOI: 10.1016/j.clinbiochem.2006.10.017. View

3.
Small D, Coombes J, Bennett N, Johnson D, Gobe G . Oxidative stress, anti-oxidant therapies and chronic kidney disease. Nephrology (Carlton). 2012; 17(4):311-21. DOI: 10.1111/j.1440-1797.2012.01572.x. View

4.
Landray M, Wheeler D, Lip G, Newman D, Blann A, McGlynn F . Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study. Am J Kidney Dis. 2004; 43(2):244-53. DOI: 10.1053/j.ajkd.2003.10.037. View

5.
Kumar N, Michelis M, DeVita M, Panagopoulos G, Rosenstock J . Troponin I levels in asymptomatic patients on haemodialysis using a high-sensitivity assay. Nephrol Dial Transplant. 2010; 26(2):665-70. DOI: 10.1093/ndt/gfq442. View